AMRN

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapeutics to improve cardiovascular health. Headquartered in Dublin, Ireland, with U.S. operations based in Bridgewater, New Jersey, the company markets its primary product, VASCEPA (icosapent ethyl), a prescription omega-3 fatty acid derived from fish oil. VASCEPA is approved by the FDA as an adjunct to maximally tolerated statin therapy to reduce cardiovascular risk in adult patients with elevated triglyceride levels. The drug addresses a significant unmet medical need in cardiovascular disease management, targeting the residual cardiovascular risk that remains even after statin treatment. Amarin generated approximately $613 million in net revenue in 2022, primarily from VASCEPA sales in the United States. The company faced significant challenges following generic competition that emerged after patent litigation concluded in 2020, substantially impacting market share and revenues. Amarin maintains commercialization rights for VASCEPA in key markets and has established partnership agreements for international distribution, including arrangements in Europe, the Middle East, and China. The company operates with a commercial infrastructure focused on cardiovascular specialists and primary care physicians. Amarin continues to explore life-cycle management opportunities for its core asset while navigating the competitive landscape created by generic icosapent ethyl products in the U.S. market.